Clinical trial
Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in…
NCT00309608 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00309608 |
|---|---|
| Title | Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes |
| Official title | A Randomised, Double-blind, Placebo-controlled, Five Parallel Groups Study Investigating the Efficacy and Safety of BI 1356 BS (1 mg, 5 mg and 10 mg Administered Orally Once Daily) Over 12 Weeks as add-on Therapy in Patients With Type 2 Diabetes and Insufficient Glycaemic Control Despite Metformin… |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | Linagliptin, Placebo, Glimepiride |
| Enrollment | 333 |
| Start date | Apr 1, 2006 |
| Primary completion | Aug 1, 2007 |
| First posted | Apr 3, 2006 |
| Last update posted | Jul 8, 2014 |
| Countries | France, Germany, Slovakia, Sweden, Ukraine, United Kingdom |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: